Top
Summary
All studies
Mortality
Serious outcomes
RCTs
RCT mortality
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All olokizumab studies
 
Feedback
Home
c19early.org COVID-19 treatment researchOlokizumabOlokizumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 olokizumab studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Mortality   Serious outcomes   RCTs   RCT mortality   All outcomes  
0 0.5 1 1.5+ All studies -50% 1 248 Improvement, Studies, Patients Relative Risk Mortality -50% 1 248 RCTs -50% 1 248 Late -50% 1 248 Olokizumab for COVID-19 c19early.org November 2024 Favorsolokizumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control RESET Samsonov (RCT) unknown, >1.5 years late 198 (total) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 study (+1 unreported RCT) c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] 9/124 6/124 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 mortality result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 serious outcome c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control RESET Samsonov (RCT) unknown, >1.5 years late 198 (total) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 Randomized Controlled Trials c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] 9/124 6/124 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 RCT mortality result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control Samsonov (DB RCT) 30% 0.70 [0.42-1.15] no improv. 21/124 30/124 Samsonov (DB RCT) 30% 0.70 [0.45-1.09] no improv. 26/124 37/124 Olokizumab COVID-19 outcomes c19early.org November 2024 Favors olokizumab Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0